Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the mechanisms of action of different classes of targeted agents for treating patients with non-Hodgkin’s lymphomas
- Discuss different classes of agents being used to treat or investigated for non-Hodgkin’s lymphoma patients
- Summarize the common toxicities associated with the various classes of agents currently in use or under exploration for the treatment of non-Hodgkin’s lymphomas
- Cite recent clinical trial results for the treatment of non-Hodgkin’s lymphomas
Topics covered include:
- Introduction
- Defining Indolent B-Cell Lymphomas
- Chemotherapy Agents for Treating Indolent Lymphomas
- Monoclonal Antibodies for Treating Indolent Lymphomas
- Radioimmunotherapy for Treating Indolent Lymphoma
- High-Dose Chemotherapy
- Vaccine Strategies for Indolent Lymphomas
- Novel Agents for Treating Indolent Lymphomas
- Defining Aggressive B-Cell Lymphomas
- Chemotherapy in Aggressive Lymphomas
- Monoclonal Antibodies for Treating Aggressive Lymphomas
- High-Dose Chemotherapy Strategies
- Novel Therapies for Treating Aggressive Lymphomas
- Treatment of Mantle Cell Lymphoma and Burkitt’s Lymphoma
- Treatment of T-Cell Lymphomas
- Conclusions
Abstract